Come up with a name for your new list and we'll add to it:
AKTivate Therapeutics was acquired by
Virax on October 17, 2014.
AKTivate Therapeutics is conducting clinical trials in breast and ovarian cancers that are resistant to chemotherapy. The trials use a molecule called triciribine phosphate monohydrate to block AKT, t…